TScan Therapeutics, Inc. (TCRX)

NASDAQ: TCRX · IEX Real-Time Price · USD
7.75
-0.05 (-0.64%)
At close: Apr 12, 2024, 4:00 PM
7.59
-0.16 (-2.06%)
After-hours: Apr 12, 2024, 4:55 PM EDT
-0.64%
Market Cap 337.94M
Revenue (ttm) 21.05M
Net Income (ttm) -89.22M
Shares Out 43.61M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,771
Open 7.84
Previous Close 7.80
Day's Range 7.49 - 8.12
52-Week Range 1.62 - 9.00
Beta 0.90
Analysts Strong Buy
Price Target 11.00 (+41.94%)
Earnings Date May 8, 2024

About TCRX

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 154
Stock Exchange NASDAQ
Ticker Symbol TCRX
Full Company Profile

Financial Performance

In 2023, TCRX's revenue was $21.05 million, an increase of 55.52% compared to the previous year's $13.54 million. Losses were -$89.22 million, 34.7% more than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for TCRX stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 41.94% from the latest price.

Price Target
$11.0
(41.94% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs...

6 days ago - GlobeNewsWire

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...

12 days ago - GlobeNewsWire

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are re...

5 weeks ago - GlobeNewsWire

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

6 weeks ago - GlobeNewsWire

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101

6 weeks ago - GlobeNewsWire

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan's abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the r...

2 months ago - GlobeNewsWire

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

2 months ago - GlobeNewsWire

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

2 months ago - GlobeNewsWire

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies

3 months ago - GlobeNewsWire

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Reported positive initial data from Phase 1 heme program at the 65 th American Society of Hematology (ASH) Annual Meeting

3 months ago - GlobeNewsWire

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical interventi...

4 months ago - GlobeNewsWire

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

4 months ago - GlobeNewsWire

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

4 months ago - GlobeNewsWire

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

4 months ago - GlobeNewsWire

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

WALTHAM, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

4 months ago - GlobeNewsWire

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Company to present poster on initial data from heme malignancies Phase 1 trial at the 65 th ASH Annual Meeting and Exposition; Company to host virtual KOL event on Monday, December 11, 2023, at 8:00 a...

5 months ago - GlobeNewsWire

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Solid tumor program uses separate screening protocol designed to identify patients in advance of treatment protocol; on track to enroll first patient in study this year

5 months ago - GlobeNewsWire

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting Company to host virtual KOL event f...

5 months ago - GlobeNewsWire

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...

7 months ago - GlobeNewsWire

TScan Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ...

7 months ago - GlobeNewsWire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

TSC-203-A0201 is TScan's fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy TSC-203-A0201 is TScan's fourth TCR-T cell ...

8 months ago - GlobeNewsWire

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report ...

8 months ago - GlobeNewsWire

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, ...

10 months ago - Business Wire

TScan Therapeutics Announces Transition of Chief Financial Officer

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T c...

10 months ago - GlobeNewsWire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

TSC-200-A0201 is TScan's third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target...

11 months ago - GlobeNewsWire